EFTR (OTC)
EFFECTOR THERAPUTCS INC
$0.000200
-0.019800 (-99.00%)
Prev close: $0.020000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Stephen T. Worland
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $0.01M
- Employees
- 15
- P/E (TTM)
- -12.57
- P/B (TTM)
- -152.62
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2024 (Q1)
|
$-2.16 | $-2.21 | +0.0483 | +2.19% |
|
Dec 2023 (Q4)
|
$-3.42 | $-1.68 | -1.7370 | -103.21% |
|
Sep 2023 (Q3)
|
$-3.25 | $-3.14 | -0.1051 | -3.34% |
|
Jun 2023 (Q2)
|
$-4.25 | $-5.04 | +0.7926 | +15.72% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$1.93M |
| Operating Expenses | $32.70M |
| Depreciation and Amortization | $111.00M |
| Research and Development | $21.62M |
| Operating Income/Loss | -$32.70M |
| Income/Loss From Continuing Operations After Tax | -$34.63M |
| Income/Loss From Continuing Operations Before Tax | -$34.63M |
| Interest Expense, Operating | $2.98M |
| Net Income/Loss | -$34.63M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$34.63M |
| Net Income/Loss Available To Common Stockholders, Basic | -$34.63M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$18.30 |
| Diluted Earnings Per Share | -$18.30 |
| Basic Average Shares | 65,260,135 |
| Diluted Average Shares | 65,260,135 |
| Assets | $27.13M |
| Current Assets | $26.25M |
| Cash | $25.40M |
| Other Current Assets | $850.00K |
| Noncurrent Assets | $881.00K |
| Fixed Assets | $190.00K |
| Other Non-current Assets | $691.00K |
| Liabilities | $26.30M |
| Current Liabilities | $25.57M |
| Accounts Payable | $1.71M |
| Interest Payable | $217.00K |
| Wages | $978.00K |
| Other Current Liabilities | $22.66M |
| Noncurrent Liabilities | $735.00K |
| Long-term Debt | $19.44M |
| Equity | $827.00K |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $827.00K |
| Liabilities And Equity | $27.13M |
| Net Cash Flow From Operating Activities | -$29.19M |
| Net Cash Flow From Operating Activities, Continuing | -$29.19M |
| Net Cash Flow From Investing Activities | -$864.00K |
| Net Cash Flow From Investing Activities, Continuing | -$864.00K |
| Net Cash Flow From Financing Activities | $35.25M |
| Net Cash Flow From Financing Activities, Continuing | $35.25M |
| Net Cash Flow | $5.20M |
| Net Cash Flow, Continuing | $5.20M |
| Comprehensive Income/Loss | -$34.63M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$34.63M |
| Other Comprehensive Income/Loss | -$26.27M |